Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma

Overview

Primary objective:

To evaluate the clinical activity of the vaccine regimen, as indicated by progression-free survival versus the clinical activity of the reference treatment.

Secondary objectives:

Safety: To describe the safety profile in both treatment groups.

Efficacy: To determine the objective clinical responses of patients in both treatment groups: complete response and partial response.

Full Title of Study: “Phase II Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic Melanoma”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 2010

Detailed Description

Eligible participants will be randomized to receive either a vaccine treatment consisting of a series of multi-antigen melanoma vaccine and GM-CSF injections, followed by high-dose IFN-α2b or only the high-dose IFN-α2b.

Interventions

  • Biological: ALVAC(2) Melanoma multi-antigen therapeutic vaccine
    • 0.5 mL, 2 cycles
  • Biological: Intron A, Interferon alpha -2b
    • 0.5 mL, 5 times per week for 4 weeks

Arms, Groups and Cohorts

  • Experimental: Study Group 1: ALVAC melanoma vaccine
    • Participants will receive a multi-antigen of modified canarypox virus (ALVAC[2]) melanoma vaccine and granulocyte macrophage colony stimulating factor (GM-CSF) every 3 weeks, followed by 4 weeks of high-dose interferon alpha-2b 5 times per week.
  • Active Comparator: Study Group 2: Interferon alpha-2b
    • Participants on 4 weeks of high-dose interferon alpha-2b 5 times per week. Participants who showed disease progression after Cycle 1 will be permitted to cross over to Group 1 treatment.

Clinical Trial Outcome Measures

Primary Measures

  • Summary of Disease Progression in Study Participants, Intent-to-treat Population
    • Time Frame: Day 0 up to 35 weeks post 1st vaccination or treatment
    • Number of evaluable study participants who had died or experienced objective disease progression (no clinical objective response to treatment as evaluated by computed tomography [CT] scans or physical examination).
  • Progression-Free Survival Time by Response Evaluation Criteria in Solid Tumor (RECIST) Criteria in the Intent-to-treat Population
    • Time Frame: Day 0 – up to 35 weeks post 1st vaccination or treatment
    • Progression-Free Survival was assessed by the Response Evaluation Criteria in Solid Tumor criteria from the computed tomography (CT) scans, as per-protocol

Secondary Measures

  • Best Overall Objective Response as Number of Participants Responding in the Intent-to-treat Population
    • Time Frame: Day 0 to 32 weeks post 1st vaccination or treatment
    • Objective response rate (ORR) is the sum of complete response (CR) and partial response (PR) Complete response = Disappearance of all target lesions. Partial response = At least a 30% decrease in the sum of longest diameter of target lesions, taking as reference the baseline sum longest diameter.
  • Best Overall Objective Response in the Intent-to-treat Population
    • Time Frame: Day 0 to 32 weeks post 1st vaccination or treatment
    • Objective response rate (ORR) is the sum of complete response (CR) and partial response (PR) Complete response = Disappearance of all target lesions. Partial response = At least a 30% decrease in the sum of longest diameter of target lesions, taking as reference the baseline sum longest diameter.
  • Best Overall Objective Response as Mean Duration of Response (Weeks) in the Intent-to-treat Population
    • Time Frame: Day 0 to 32 weeks post 1st vaccination or treatment
    • Objective response rate (ORR) is the sum of complete response (CR) and partial response (PR) Complete response = Disappearance of all target lesions. Partial response = At least a 30% decrease in the sum of longest diameter of target lesions, taking as reference the baseline sum longest diameter.
  • Number of Participants Reporting a Grade 3 or Grade 4 Adverse Events by Preferred Term
    • Time Frame: Day 0 to 12 months post last vaccination
    • Common Terminology Criteria for Adverse Events (CTCAE) definitions: Grade 3 is a severe adverse event; Grade 4 is a life-threatening or disabling adverse event.

Participating in This Clinical Trial

Inclusion Criteria :

  • A pathologically confirmed diagnosis of malignant melanoma with at least one measurable metastatic lesion with a minimum lesion size of 20 mm, based on radiological assessment (or 10 mm if assessed by spiral computed tomography [CT] scan ) as per Response Evaluation Criteria in Solid Tumors (RECIST) criteria (Stages IIIc, IVa, or IVb only, according to the American Joint Committee on Cancer (AJCC) staging system for melanoma). Cutaneous metastasis (assessed by physical examination) must be at least 10 mm. CT scan or magnetic resonance imaging (MRI) is required to rule out brain metastases.
  • Patients who received prior treatment for their metastatic disease must have objective evidence of disease progression.
  • Aged ≥ 18 years on the day of inclusion
  • IRB-approved informed consent form signed
  • Able to attend all scheduled visits and to comply with all trial procedures
  • For a woman, inability to bear a child or negative serum pregnancy test
  • For a woman of child-bearing potential, using an effective method of contraception or abstinence during the study and at least 4 weeks after the last study treatment
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and a life expectancy of at least 6 months.
  • Adequate hematologic, hepatic, and renal function (at pre-defined laboratory values).
  • Fully recovered from surgery, if applicable.

Exclusion Criteria :

  • Receipt of two or more previous therapies for metastatic melanoma.
  • Receipt of chemotherapy or another therapy for metastatic melanoma within the last four weeks
  • Receipt of adjuvant interferon therapy within the last six months
  • Concurrent receipt of radiotherapy for the metastatic disease, unless for palliative purposes
  • Participation in another clinical trial within the four weeks preceding the first trial treatment
  • Planned participation in another clinical trial during the present trial period
  • Known Human Immunodeficiency Virus (HIV) infection or hepatitis B (Ag HBs) or hepatitis C seropositivity
  • Presence of active autoimmune disease (excluding vitiligo)
  • Systemic hypersensitivity to bovine products or to any of the vaccine components, including egg products or Neomycin (used to prepare the vaccine), or history of a life-threatening reaction to granulocyte-macrophage colony stimulating factor (GM-CSF) or interferon (IFN)-α2b
  • Current alcohol or drug addiction that may interfere with the ability to comply with trial procedures
  • Significant co-morbid medical conditions, including pre-existing renal disease, cirrhosis, or major depression, which in the estimation of the investigator would preclude safe participation in the study or the accurate interpretation of data.
  • A calculated glomerular filtration rate (GFR) <60 mL/min (based on the Cockroft-Gault formula).
  • Previous receipt of a modified canarypox virus (ALVAC)-based vaccine.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Sanofi Pasteur, a Sanofi Company
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Medical Director, Study Director, Sanofi Pasteur Inc.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.